Corvus Pharmaceuticals, Inc. (CRVS) News
Latest headlines that mention CRVS, newest first · each headline opens the original publisher
- Last price
- $10.25
- Day change
- +1.99%
- Next earnings
- 2026-11-03
CRVS headlines
latest coverageSoquelitinib advances across multiple indications, with cash runway extended into 2028.
Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
CRVS news alerts
Get an alert by email or push when a new headline mentions CRVS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.